Treatment of benign breast diseases by nomegestrol acetate. Results of a controlled trial;L'ACETATE DE NOMEGESTROL DANS LE TRAITEMENT DES MASTOPATHIES BENIGNES. RESULTATS D'UN ESSAI CONTROLE

Sein

Volumn 6, Issue 1, 1996, Pages 19-23

  Pons, J Y ^a   Bernard, A M ^b   Thomas, J L ^b  

^a CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^b Dept Rech et Devmt Cliniques   (France)

Author keywords

benign breast disease; mastalgia; nomegestrol acetate

Indexed keywords

NOMEGESTROL ACETATE; PLACEBO;

ADULT; ARTICLE; BREAST DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; HUMAN; MAMMOGRAPHY; MASTALGIA;

EID: 0030006839     PISSN: 11631961     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. BASDEVANT A., PÉLISSIER C., CONARD J., DEGRELLE H., GUYENE T., THOMAS J.L., Effects of nomegestrol acetate (5 mg/j) on hormonal, metabolic and hemostatic parameters in premenopausal women. Contraception, 1991, 44 : 599-605.
2. BAZIN B., THÉVENOT R., BORSAUX C., PARIS J., Effect of nomegestrol acetate, a new 19-nor-progesterone derivative, on pituitary-ovarian function in women. Br. J. Obstet. Gynaecol., 1987, 94 : 1199-1204.
3. BOTELLA J., DURANTI E., Duc I., COGNET A.M., DELANSORNE T., PARIS J., Inhibition by nomegestrol acetate and other synthetic progestins on proliferation and progesterone receptor content of T47-D human breast cancer cells. J. Steroid Biochem. Molec. Biol., 1994; 50 : 41-47.
4. BOTELLA J., DURANTI E., DUC I., DELANSORNE R., PARIS J., Lack of estrogenic potential of progesterone-derived as compared to 19 nor-testosterone-derived progestins. IX International Congress on Hormonal Steroids, Dallas 1994, A103.
5. COHEN A., DENIS C., THOMAS J.L., Traitement des femmes en périménopause par 5 mg/j d'acétate de nomégestrol, 20 jours par cycle. Contracept. Fertil. Sex.., 1981 ; 304 : 560-563.
6. COUZINET B., PHOLSENA M., THOMAS J.L., SCHAISON G., Antigonadotropic effect of nomegestrol acetate, a new 19-norprogesterone derivative, in women. 75th Annual Meeting of the Endocrine Society, Las Vegas 1993.
7. DORANGEON P., THOMAS J.L., GILLERY P., LUMBROSO M., HAZARD M.C., Short term effects on lipids lipoproteins of two progestogens used in postmenopausal replacement therapy. Eur. J. clin. Res., 1992, 3 : 187-193.
8. DORANOEON P., THOMAS J.L., CHOISY H., LUMBROSO M., HAZARD M.C., Effects of nomegestrol acetate on carbohydrate metabolism. Diabete Metab., 1993, 16 : 441-445.
9. DUC I., BOTELLA J., GILLET J.Y., DUFORESTEL T., PARIS J., Nomegestrol acetate binding to cytosolic progesterone receptor in human mammary gland. Med. Sci. Res., 1990, 18 : 57-58.
10. DUC I., BOTELLA J., GILLET J.Y., DELANSORNE R., PARIS J., Liaison de l'acétate de nomégestrol aux récepteurs de la progestérone de l'endomètre et du tissu mammaire humain. Contracept. Fertil. Sex., 1991, 19 : 995-997.
11. LEFRANC J.P., TRANBALOC P., ALLIER-PINTO S., BALLA-DUR A., BLONDON J., Les mastopathies bénignes. Encycl. Méd. Chir. (Paris-France), Gynécologie 840 A10, 3-1990, 10 p.
12. MAUVAIS-JARVIS P., Le traitement hormonal des mastopathies bénignes. Bull. Cancer., 1991, 78 : 365-371.
13. PARIS J., THÉVENOT R., BONNET P., GRANERO M., The pharmacological profile of TX 066 (17 α-acetoxy-6-methyl-19-nor-4,6-pregna-diene-3,20-dione), a new oral progestative. Arzneim. Forsch./Drug. Res., 1983, 33 (1) : 710-715.
14. VORHERR H., Fibrocystic breast disease : pathophysiology. pathomorphology. clinical picture and management. Am. J. Obstet. Gynecol., 1986, 154 : 161-179.